183 related articles for article (PubMed ID: 37585188)
21. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
23. Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
Allen PB; McCook-Veal AA; Switchenko JM; Paulino DM; Niyogusaba T; Baird KM; Tarabadkar ES; Lechowicz MJ
Cancer; 2023 Feb; 129(4):541-550. PubMed ID: 36523150
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
Diamandidou E; Colome M; Fayad L; Duvic M; Kurzrock R
J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):914-24. PubMed ID: 10365922
[TBL] [Abstract][Full Text] [Related]
25. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
[TBL] [Abstract][Full Text] [Related]
26. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.
Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG;
Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564
[TBL] [Abstract][Full Text] [Related]
27. Mycosis fungoides in young patients: clinical characteristics and outcome.
Crowley JJ; Nikko A; Varghese A; Hoppe RT; Kim YH
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):696-701. PubMed ID: 9591813
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
Suzuki SY; Ito K; Ito M; Kawai K
J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
[TBL] [Abstract][Full Text] [Related]
29. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
30. Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome.
Patrawala SA; Broussard KC; Wang L; Zic JA
Dermatol Online J; 2016 May; 22(5):. PubMed ID: 27617516
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
Miyashiro D; Sanches JA
Int J Dermatol; 2022 Apr; 61(4):442-454. PubMed ID: 34435672
[TBL] [Abstract][Full Text] [Related]
32. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement.
Hodak E; Amitay-Laish I; Feinmesser M; Davidovici B; David M; Zvulunov A; Pavlotsky F; Yaniv I; Avrahami G; Ben-Amitai D
J Am Acad Dermatol; 2014 Jun; 70(6):993-1001. PubMed ID: 24629999
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
Kim YH; Chow S; Varghese A; Hoppe RT
Arch Dermatol; 1999 Jan; 135(1):26-32. PubMed ID: 9923777
[TBL] [Abstract][Full Text] [Related]
34. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
35. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.
van Doorn R; Van Haselen CW; van Voorst Vader PC; Geerts ML; Heule F; de Rie M; Steijlen PM; Dekker SK; van Vloten WA; Willemze R
Arch Dermatol; 2000 Apr; 136(4):504-10. PubMed ID: 10768649
[TBL] [Abstract][Full Text] [Related]
36. Transformed mycosis fungoides: clinicopathological features and outcome.
Barberio E; Thomas L; Skowron F; Balme B; Dalle S
Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
[TBL] [Abstract][Full Text] [Related]
37. Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome.
Novelli S; García-Muret P; Mozos A; Sierra J; Briones J
Leuk Lymphoma; 2016 May; 57(5):1060-6. PubMed ID: 27096891
[TBL] [Abstract][Full Text] [Related]
38. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
[TBL] [Abstract][Full Text] [Related]
39. Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials.
Farabi B; Seminario-Vidal L; Jamgochian M; Akay BN; Atak MF; Rao BK; Karagaiah P; Grabbe S; Goldust M
J Cosmet Dermatol; 2022 Jul; 21(7):2742-2748. PubMed ID: 34687485
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.
Benner MF; Jansen PM; Vermeer MH; Willemze R
Blood; 2012 Feb; 119(7):1643-9. PubMed ID: 22160616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
